With this funding, ERC researchers can test how their scientific work could impact the society.<\/p>\n
Four Irish researchers have won Proof of Concept grants from the European Research Council (ERC).<\/p>\n
Funding for the first round this year is worth more than \u20ac27m, and is divvied among 182 researchers with ideas that show potential for commercial or societal impact. Each individual grant is worth \u20ac150,000.<\/p>\n
Some of the ideas include developing 3D-printed \u201cbio-inspired\u201d electronics, a tool to help doctors protect vital parts of the brain during surgery, or an advanced ready-made breast cancer vaccine.<\/p>\n
University College Dublin (UCD) researcher Prof Niamh Nowlan is one such winner, who received ERC funding to further her work around new treatments for a broad range of paediatric growth disorders.<\/p>\n
Nowlan is a professor of biomedical engineering at the UCD School of Mechanical and Materials Engineering and a fellow of the UCD Conway Institute.<\/p>\n
Her project, called \u2018Grow-Reg\u2019, will attempt to identify specific cell surface markers that aid in the growth in children\u2019s bones to help develop treatments designed to speed up or slow down growth of one or more bones without systemic drugs or surgeries.<\/p>\n
\u201cAdvancing basic research closer to patients (especially babies and children), is hugely rewarding and we are excited to get started,\u201d said Nowlan. Grow-Red builds on a previous ERC-funded project led by Nowlan.<\/p>\n
\u201cBy creating the foundation for a targeted delivery platform capable of modulating growth plate activity with high anatomical precision, we hope to ultimately enable new treatments for a broad range of paediatric growth disorders, reduce reliance on invasive surgery and improve the safety and specificity of existing biologic therapies.\u201d<\/p>\n
Meanwhile, two University of Galway researchers also succeeded in receiving Proof of Concept grants. Led by systems biomedicine professor Ines Theile, \u2018iChatRD\u2019 aims to develop a user-centred clinical decision support system to diagnose rare and inherited metabolic diseases.<\/p>\n
\u201cWhen exploring avenues for translating our fundamental research on digital metabolic twins into patient-focused applications, we kept encountering a major challenge: the richest clinical information exists as free text \u2013 the language of a human, not of a computer,\u201d Theile said.<\/p>\n
\u201cChatRD bridges this gap, by enabling metabolic modelling and natural language work together to suggest candidate diagnoses for inherited metabolic diseases.<\/p>\n
\u201cThe ERC Proof of Concept grant now helps us take ChatRD into the real world, by working directly with clinicians to help shorten the diagnostic odyssey that may burden rare disease patients for years.\u201d<\/p>\n
The second project, called \u2018GelEV\u2019 will focus on developing technology that could improve regenerative medicine delivery to injured tissue sites. Led by Meadhbh Brennan, the project is engineering a hyaluronic acid hydrogel for better delivery to extracellular vesicles.<\/p>\n
University of Limerick also bagged a grant win with a project called \u2018Eve Heals\u2019 that hopes to heal diseases affecting the skin using in vitro engineered living substitutes. The project is led by Dimitrios Zevgolis, who also works across institutes at UCD.<\/p>\n
\u201cMany of today\u2019s innovations begin with a researcher asking a fundamental question. These 182 projects show that curiosity-driven science and real-world impact go hand in hand,\u201d said Ekaterina Zaharieva, the European commissioner for start-ups, research and innovation.<\/p>\n
\u201cWith Proof of Concept funding, ERC researchers can test how their discoveries could become new treatments, technologies, services or solutions that benefit people across Europe.\u201d<\/p>\n
2026\u2019s first Proof of Concept round invited 15pc more proposals this year compared to a year ago, the ERC said. Applications for the second round are open, with September deadline.<\/p>\n